AstraZeneca, Handa settlements in US case over Seroquel XR get final approval
MLex Summary: AstraZeneca and Handa Pharmaceuticals’ settlements with direct purchasers of Seroquel XR totaling $51.4 million were granted final approval, resolving US antitrust claims alleging an unlawful agreement to delay market...To view the full article, register now.
Already a subscriber? Click here to view full article